drugset / Trial / NCT00584896

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

NCT00584896 ↗

Phase 3 Terminated 1000 enrolled Point Biomedical
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine if the use of PB127 with cardiac ultrasound assists in the diagnosis or exclusion of coronary artery disease.

Timeline

Start
2007-10
Primary completion
2008-07
Completion
2008-07

Outcome

Outcome not reported

Stopped (Business): “Discontinued PB127 development program for business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject PB127 Diagnostic / imaging agent 0.062 mg/kg Intravenous